Alnylam Pharmaceuticals Reports Strong Q1 2026 Earnings with Record Revenue
Alnylam Pharmaceuticals (ALNY) reported Q1 2026 earnings with total net product revenues of $1.036 billion, a 121% increase year over year. The company surpassed the $1 billion revenue mark for the first time, driven by strong performance in its TTR franchise and rare disease portfolio. The earnings call highlighted growth in U.S. TTR revenues and international expansion, despite some challenges in gross margin.
Tickers: $ALNY
Topics: earnings report financial results product revenue revenue growth